<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03217487</url>
  </required_header>
  <id_info>
    <org_study_id>2017KYPJ051</org_study_id>
    <nct_id>NCT03217487</nct_id>
  </id_info>
  <brief_title>Corneal Epithelial Autograft for LSCD</brief_title>
  <official_title>A Randomized Controlled Clinical Trial of Corneal Epithelial Autograft for the Treatment of Limbal Stem Cell Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chunxiao Wang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to explore whether femtosecond laser-assisted corneal epithelial
      autograft is more effective than limbal conjunctival autograft for ocular surface
      reconstruction in patients with limbal stem cell deficiency (LSCD).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 25, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Restoration of corneal surface in the diseased eye</measure>
    <time_frame>1 year</time_frame>
    <description>Restoration of a completely epithelized, stable, and avascular corneal surface in the diseased eye.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Restoration of corneal surface in the fellow eye</measure>
    <time_frame>1 year</time_frame>
    <description>Restoration of a completely epithelized, stable, and avascular corneal surface in the fellow eye.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uncorrected and best-corrected visual acuity in both eyes</measure>
    <time_frame>1 year</time_frame>
    <description>To measure changes of uncorrected and best-corrected visual acuity using ETDRS chart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal power, astigmatism and aberration in both eyes</measure>
    <time_frame>1 year</time_frame>
    <description>To changes of corneal power, astigmatism and aberration using autorefractor keratometer and wavefront aberrometer respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal sensation in both eyes</measure>
    <time_frame>1 year</time_frame>
    <description>To assess corneal sensation using Cochet-Bonnet esthesiometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal thickness in both eyes</measure>
    <time_frame>1 year</time_frame>
    <description>To measure corneal thickness using anterior segment optical coherence tomography (AS-OCT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Density of stromal nerve and stromal keratocytes in both eyes</measure>
    <time_frame>1 year</time_frame>
    <description>To assessing density of stromal nerve and stromal keratocytes using in vivo confocal microscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reconstruction of limbal palisades of Vogt in the diseased eye</measure>
    <time_frame>1 year</time_frame>
    <description>To assessing reconstruction of limbal palisades of Vogt using in vivo confocal microscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal haze in both eyes</measure>
    <time_frame>1 year</time_frame>
    <description>To measuring corneal haze using in vivo confocal microscopy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Limbal Stem Cell Deficiency</condition>
  <arm_group>
    <arm_group_label>Corneal epithelial autograft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Femtosecond laser assisted corneal epithelial autograft from the other eye in the treatment of LSCD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Limbal conjunctival autograft</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diamond knife assisted limbal conjunctival autograft from the other eye in the treatment of LSCD</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Corneal epithelial autograft</intervention_name>
    <description>Epithelial tissue, equal in area to the diseased eye's cornea bed, will be obtained from the fellow eye using femtosecond laser technology. This corneal epithelial autograft is then ready for transplantation on the disease eye, following removal of scarred and diseased epithelium.</description>
    <arm_group_label>Corneal epithelial autograft</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Limbal conjunctival autograft</intervention_name>
    <description>A 3- to 5- clock hour limbal-conjunctival autograft will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following removal of scarred and diseased epithelium.</description>
    <arm_group_label>Limbal conjunctival autograft</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Femtosecond laser</intervention_name>
    <description>A commercial femtosecond laser to create a particular shaped graft for transplantation</description>
    <arm_group_label>Corneal epithelial autograft</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Diamond knife</intervention_name>
    <description>A diamond knife to create a particular shaped limbal graft for transplantation</description>
    <arm_group_label>Limbal conjunctival autograft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Unilateral LSCD secondary to ocular burns, with the duration of disease of at least 24
             months at the time of screening visit;

          2. Presence of superficial neo-vascularization affecting at least 2 cornea quadrants and
             involving central cornea;

          3. Informed consent signed by patient or legal guardian. Having the ability to comply
             with study assessments for the full duration of the study.

        Exclusion Criteria:

          1. LSCD of mild degree, with less than 2 quadrants of neo-vessel invasion and without
             central cornea involvement;

          2. LSCD by ocular surface disorders other than pterygium;

          3. Eyelids malposition;

          4. The center corneal thickness&lt;450µm, the depth of corneal opacity &gt; 150µm;

          5. High myopia with a spherical equivalent of -15.0 D or less;

          6. Corneal or ocular surface infection within 30 days prior to study entry;

          7. Ocular surface malignancy;

          8. Uncontrolled diabetes with most recent Hemoglobin A1c greater than 8.5%;

          9. Renal failure with creatinine clearance&lt; 25ml/min;

         10. Alanine aminotransferase &gt; 40IU/L, or aspartate aminotransferase &gt; 40IU/L;

         11. Platelet levels &lt; 150,000 or &gt; 450,000 per microliter;

         12. Hemoglobin &lt; 12.0 g/dL (male) or &lt; 11.0 g/dL (female);

         13. Prothrombin time &gt; 16s and activated partial thrombin time &gt; 35s in patients not
             accepting anticoagulant therapy; An international normalized ratio greater than 3 in
             patients accepting anticoagulant therapy;

         14. Pregnancy (positive test) or lactation;

         15. Participation in another simultaneous medical investigation or clinical trial;

         16. Severe cicatricial eye disease; Conjunctival scarring with fornix shortening;

         17. Ocular comorbidities that affect the prognosis of transplantation, such as advanced
             glaucoma or retinal diseases;

         18. Severe dry eye disease as determined by Schirmer's test &lt; 2mm at least in one eye;

         19. Any medical or social condition that in the judgment of the investigator would
             interfere with or serve as a contraindication to adherence to the study protocol or
             ability to give informed consent;

         20. Signs of current infection, including fever and treatment with antibiotics;

         21. Active immunological diseases;

         22. History of allo-limbal transplantation, penetrating keratoplasty or anti-glaucoma
             filtering surgeries.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yizhi Liu, M.D.Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ting Huang, M.D.Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yingfeng Zheng, M.D.Ph.D.</last_name>
    <phone>+8613922286455</phone>
    <email>yingfeng.zheng@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center, Sun Yat-sen Univerisity</name>
      <address>
        <city>Guanzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yingfeng Zheng, M.D. Ph.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2017</study_first_submitted>
  <study_first_submitted_qc>July 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2017</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Chunxiao Wang</investigator_full_name>
    <investigator_title>Clinical investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

